The first article in the series "Medical Sovereignty"

Health Sovereignty: Why It's Not a Technological Issue, But a Crossroads of Finance and Governance <br />Over the past decade, global healthcare discussions have been dominated by technological terminology—AI, data platforms, precision medicine, digital health, blockchain, and cloud systems. These innovations promise to improve efficiency, reduce costs, and reshape the healthcare ecosystem. However, a core issue has been systematically ignored: if a society cannot decide who has the power to make healthcare decisions, then even the most advanced technology ultimately becomes a tool manipulated by others. This is precisely why "health sovereignty" has risen to become an institutional issue. It not only concerns health governance but also involves national economic resilience, investment risk, global capital flows, and financial strategies within the ESG (Environmental, Social, and Governance) framework.
In 2025, declining global development aid for health highlights the financial urgency of healthcare sovereignty. As health data increasingly concentrates in the hands of multinational tech giants, nations and investors face not a shortage of technology, but rather the risk of lost capital returns and the loss of sovereignty. Developing countries can generate $2-4 in economic returns for every $1 invested in health, but this multiplier effect is weakened by the loss of sovereignty. This not only impacts public budgets but also reshapes the landscape of mergers and acquisitions in the healthcare industry and the direction of venture capital investment, emphasizing the role of sovereignty as an "intangible asset" in the global supply chain. For example, the US freeze on foreign aid has led to a global shortage of health funds, affecting the implementation of everything from malaria trials to AIDS programs, thereby amplifying geopolitical risks and suppressing the attractiveness of healthcare investment in emerging markets.

(Image caption) The involvement of AI and big data technologies may exclude 5 billion people globally, exacerbating structural inequality.

I. What is medical sovereignty?
Healthcare sovereignty transcends medical technology or industrial policy. It refers to a society's capacity for autonomous decision-making, data control, and institutional choices regarding health matters, which, from a financial perspective, directly impacts investment attractiveness and risk management. This includes:

• Ownership and Access to Medical Data : Who Controls Patient Data? For example, clinical data is often considered "co-constructed," preventing patients from having exclusive rights. Meanwhile, tech companies collect massive amounts of data through health apps, raising privacy and sovereignty disputes. In investment, data sovereignty ensures compliance, avoids fines, and enhances asset value. Considering the EU's GDPR or China's Data Security Law, multinational healthcare funds need to assess data sovereignty risks to prevent capital outflows or legal disputes from impacting returns. In Canada, the lack of AI legislation has placed health data sovereignty at serious risk, particularly for Indigenous communities, potentially leading to data being used by foreign entities, weakening local innovation, and amplifying economic dependence.
• Ultimate Judgment in Health Decisions : In public health emergencies, should decisions rest with the state, institutions, or transnational organizations? International health regulations may impose restrictions on individual freedom and collect private data, challenging national sovereignty and impacting cross-border investment flows. This is particularly evident in the post-pandemic supply chain restructuring; if a nation loses its decision-making power, it could lead to the relocation of pharmaceutical manufacturing overseas, weakening local economic contributions and amplifying geopolitical risks. Public health is considered crucial to national security, necessitating strengthened health infrastructure and cybersecurity to prevent damage to economic sovereignty.
• The Boundary Between Public Health and Commercial Systems : How to Divide Public Interest into Profit? The influence of big tech companies in healthcare is driving a shift in public health ethics, emphasizing sovereignty, equity, and solidarity—key evaluation metrics in ESG investing. Investors are increasingly focused on the "sovereignty score" of healthcare companies, as ignoring this can lead to stock price volatility or shareholder lawsuits, especially in aging markets. Planetary health issues further complicate this boundary, calling for a balanced allocation of resources across current and future generations in the health sector to maintain economic sustainability.
• Power Distribution : Balancing between individuals, nations, and transnational institutions. The rise of indigenous data sovereignty movements, with long-excluded groups vying for data governance rights to prevent historical injustices from repeating themselves, is crucial for ESG-oriented healthcare investment funds. From a financial perspective, this has driven the rise of "sovereign bonds" or special funds focusing on localized healthcare investment to hedge against global uncertainty. The health sovereignty models of Cuba, Brazil, and Thailand provide examples: Cuba emphasizes domestic production, Brazil focuses on equitable distribution, and Thailand integrates regional cooperation, all enhancing economic resilience and attracting international capital.

As these powers are devolved, the healthcare issue shifts from a matter of "efficiency and cost" to a crisis of sovereignty and governance. Global health strategies emphasize sovereign protection in emergencies, but also expose institutional lags that lead to declining health spending in low-income countries, impacting economic growth. This is not only a health issue but also involves fiscal policy, such as optimizing the ratio of health spending to GDP to maintain long-term economic stability. Persistent economic uncertainty, rising debt burdens, persistent inflation, and shrinking fiscal space all amplify the financial challenges to healthcare sovereignty.

II. Why is healthcare sovereignty becoming a global issue?
Three trends are accelerating this shift, amplifying investment risks and opportunities from a financial perspective:

1. The high centralization of health data : Medical data has become a strategic resource for multinational platforms and technology companies. The involvement of AI and big data could exclude 5 billion people globally, exacerbating structural inequalities. For example, the need for decentralized infrastructure is rising to meet data sovereignty requirements, otherwise investors face soaring compliance costs. This is driving valuation growth in the medical data market, projected to reach hundreds of billions of dollars by 2030, but sovereignty disputes could trigger antitrust investigations, impacting the performance of technology stocks. Investing in R&D and the manufacturing ecosystem positions health as a strategic area of economic sovereignty, attracting private capital and driving growth.
2. Public health events are increasingly crossing borders : pandemics, chronic diseases, and aging populations are driving decision-making beyond national borders. African leaders are prioritizing health financing as an economic imperative, promoting "African health sovereignty" to reduce dependence on external aid as disease outbreaks increase. This is reshaping global health financing channels, geo-redirecting investment towards local manufacturing, and creating emerging market opportunities, such as the VC boom in the African pharmaceutical industry, which is projected to grow at an annual rate exceeding 15%. Health is seen as crucial for national strength, and in the face of economic uncertainty and sovereignty threats, integrated health investments are needed to improve overall economic performance.
3. Technological solutions are outpacing institutional responses : AI can rapidly deploy diagnostics and predictions, but governance lags behind. While AI healthcare applications in the Global South hold immense potential, they face challenges from poverty and resource scarcity, amplified by declining funding. Clinic spending is projected to increase, while hospital spending is lower, but a lack of sovereignty will dampen returns. This is prompting investors to turn to "sovereignty-first" healthcare ETFs, focusing on countries with strong governance frameworks to diversify risk. Rising healthcare costs will create financial difficulties for providers, emphasizing risk management and resilience.

As a result, many countries possess advanced healthcare systems but have lost their choice. Regional dialogues are calling for reforms, shifting towards regional leadership rather than donor-led initiatives to enhance economic sovereignty. This not only impacts public finances but also shapes private equity allocation strategies in healthcare, emphasizing sovereignty as a long-term value driver. Cooperation to improve well-being and public health is fundamental to economic recovery.

III. Why isn't this a question of "whether technology can solve it"?
The core of healthcare sovereignty lies not in technological advancement, systemic intelligence, or decentralization, but in who decides the use, licensing, and termination of technology. Prematurely focusing on technical details often masks systemic flaws, and from a financial perspective, this amplifies investment risks.
For example, the revolutionary benefits of AI in healthcare (such as personalized interactions and predictive analytics) are being dominated by big tech, raising ethical concerns and increasing ESG risks. Proposed pandemic treaty proposals could erode national sovereignty and impact capital flows through vaccine passport tracking compliance. The tribal health data sovereignty movement demonstrates that technology cannot solve historical exclusion issues, and healthcare organizations need to integrate ESG principles to manage risks and create opportunities. This manifests in investment portfolios as a "sovereignty premium"—healthcare assets with strong sovereignty often enjoy higher valuation multiples.
Therefore, defining the framework of the problem—such as the role of sovereignty in a global health crisis—is far more important than providing technological solutions, especially given that health spending in high-income countries far exceeds that in low-income countries. This requires financial analysts to incorporate sovereignty into their risk models and predict potential market volatility, such as adjustments in pharmaceutical stocks due to sovereignty disputes.

(Image caption) The role of sovereignty in global health crises – far more important than providing technological solutions

IV. Why does GFM focus on healthcare sovereignty?
As a technology and finance media outlet, GFM does not position itself as a technology provider or policy advocate. We focus on:

• Institutional Definition of Healthcare Issues : How to Analyze Power Transfer from a Financial Perspective? For example, health as economic sovereignty attracts private capital and drives R&D investment. This includes assessing the impact of a lack of sovereignty on IPOs and M&A, and helping investors identify high-potential areas.
• The hierarchical shift of decision-making power : cross-border case studies, such as the health sovereignty models of Cuba, Brazil, and Thailand, and economic self-determination in health financing in Africa. These cases provide financial insights, such as how localization strategies can increase GDP contribution and attract foreign investment.
• Oversimplification of the discussion : Avoid reducing governance risks to technical issues, especially within the ESG framework, where healthcare affairs contribute strategies to enhance transparency and ethics. This has driven the application of ESG ratings in the healthcare industry, influencing fund flows.

This special issue aims to establish a long-neglected framework to explore the impact of healthcare sovereignty on investment, risk, and the global economy, such as hospital ESG motivations and payer actions. Through in-depth analysis, we reveal how sovereignty becomes an "invisible moat" for the healthcare industry, influencing long-term capital returns.

V. Special Topic Explanation: "Medical Sovereignty" will be continuously updated:

• This paper breaks down institutional issues and analyzes the impact of data sovereignty on investment from a financial perspective.
• Cross-border structural comparisons (such as global health reform proposals and Canada's sovereignty over medical data).
• Long-term risk observation in health governance, including the application of ESG frameworks in the healthcare industry.

This report does not provide investment advice or policy recommendations.

In the medical field, what is truly scarce is never technology, but the ability to determine when to use it and when to refuse it. This is not only a health issue, but also a point of intersection between finance and sovereignty, affecting global capital allocation and economic resilience.